Capricor reports primary success of HOPE‑3 trial while cardiac endpoint misses significance
Capricor Therapeutics disclosed that its HOPE‑3 study achieved its main efficacy goal, showing a statistically meaningful reduction in upper‑limb disease progression in Duchenne muscular dystrophy patients, with a p‑value of 0.029. The same trial’s cardiac measure of left‑ventricular ejection fraction did not reach statistical significance overall, though a pre‑specified subgroup with existing cardiomyopathy saw an approximate 2.8‑point improvement. The company has filed a 30,000‑page amendment to the FDA and the review remains ongoing, with a PDUFA target action date of November 22, 2026.
Why it matters
The primary endpoint success could strengthen Capricor’s Biologics License Application and support a refined indication for treating upper‑limb impairment, while the lack of significance on the cardiac endpoint may limit claims for heart‑related benefits. The ongoing FDA review means the decision timeline will affect the company’s market launch and revenue expectations.
Key facts
- 1The HOPE‑3 trial met its primary efficacy endpoint with a p‑value of 0.029. finance.yahoo.com
- 2The absolute difference between treatment and placebo on the primary scale was 1.1 points. finance.yahoo.com
- 3Overall change in left‑ventricular ejection fraction did not achieve statistical significance. tradingview.com
- 4In patients with pre‑existing cardiomyopathy, ejection fraction improved by about 2.8 percentage points versus placebo. finance.yahoo.com
- 5Capricor submitted a 30,000‑page amendment to the FDA in August, including 24‑month open‑label data. finance.yahoo.com
- 6The FDA’s PDUFA target action date for the biologics license application is November 22, 2026. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.